Rik van der Kant is an assistant professor with a dual position at the Vrije Universiteit Amsterdam and the Alzheimer Center of the Amsterdam University Medical Center. His lab studies the molecular mechanisms underlying Alzheimer’s disease (AD) and other neurodegenerative diseases in the elderly. Work in the van der Kant labs focusses on the role of lipid metabolism in disease and the use of human iPSC-derived neuronal models to discover how lipids contribute to early disease progression.
Optional to include:
Rik van der Kant is the co-founder of the Amsterdam Neuroscience CANDIDATE center, an academic translational drug development for neurogenerative diseases. Dr. van der Kant also leads a phase 2a clinical trial in early AD (CHOlesterol Conversion for Late onset AD, CHOCOLAD) to evaluate the efficacy of low-dose Efavirenz as a brain cholesterol- and Tau lowering intervention.
